公开(公告)号：US20240360196A1

公开(公告)日：2024-10-31

申请号：US18607387

申请日：2024-03-15

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind RAJPAL ,  Shobha Chowdary POTLURI ,  Laurent POIROT ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Donna Marie STONE ,  Barbra Johnson SASU

IPC: C07K14/705 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/3069 ,  C12N5/0636 ,  A61K2039/5156 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising



an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.

公开(公告)号：US20240343783A1

公开(公告)日：2024-10-17

申请号：US18420525

申请日：2024-01-23

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Michael C. Milone ,  Enxiu Wang

IPC: C07K16/18 ,  C07K14/705 ,  C07K14/735

CPC classification number: C07K16/18 ,  C07K14/70503 ,  C07K14/70535 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20240294639A1

公开(公告)日：2024-09-05

申请号：US18662315

申请日：2024-05-13

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

Inventor： Michel Sadelain ,  Reuben Benjamin ,  Dimiter S. Dimitrov ,  Yang Feng

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/3061 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70

Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：US20240287157A1

公开(公告)日：2024-08-29

申请号：US18595641

申请日：2024-03-05

Applicant: Regeneron Pharmaceuticals, Inc

Inventor： Wai-Hang Leung

IPC: C07K14/715 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/73

CPC classification number: C07K14/7155 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70575 ,  C07K2319/70

Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

公开(公告)号：US12065501B2

公开(公告)日：2024-08-20

申请号：US17072434

申请日：2020-10-16

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： John T. Ngo

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/71 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/09 ,  C12N9/50

CPC classification number: C07K16/30 ,  C07K14/705 ,  C07K16/2863 ,  C07K16/462 ,  C07K19/00 ,  C12N5/0693 ,  C12N9/50 ,  C07K16/28 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74

Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.

公开(公告)号：US20240262878A1

公开(公告)日：2024-08-08

申请号：US18567159

申请日：2022-06-07

Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： Chia Hao MO

IPC: C07K14/47 ,  A61K41/00 ,  C12N13/00

CPC classification number: C07K14/4747 ,  A61K41/00 ,  C12N13/00 ,  C07K2319/70

Abstract: This invention relates to a modified gasdermin protein having a photoactivatable linker inserted between the C-terminal domain and N-terminal domain a gasdermin protein, nucleic acids and vectors encoding the modified gasdermin protein, and methods of using the modified gasdermin protein to introduce agents into cells and facilitate the treatment of diseases or conditions.

公开(公告)号：US20240228583A1

公开(公告)日：2024-07-11

申请号：US18289037

申请日：2022-05-03

Applicant: Keros Therapeutics, Inc.

Inventor： Jasbir S. SEEHRA ,  Jennifer LACHEY ,  Claire TSENG ,  Elissa FURUTANI ,  Christopher R. ROVALDI

IPC: C07K14/71 ,  A61K47/68 ,  A61P9/12 ,  A61P13/12 ,  A61P19/00 ,  A61P21/00 ,  C07K14/78

CPC classification number: C07K14/71 ,  A61K47/68 ,  A61P9/12 ,  A61P13/12 ,  A61P19/00 ,  A61P21/00 ,  C07K14/78 ,  C07K2319/30 ,  C07K2319/70

Abstract: The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and/or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

公开(公告)号：US20240192197A1

公开(公告)日：2024-06-13

申请号：US18554490

申请日：2022-04-07

Applicant: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Hai JIANG ,  Shishuang CHEN ,  Yankai CHU

IPC: G01N33/50 ,  C07K14/47

CPC classification number: G01N33/5023 ,  C07K14/4747 ,  C07K2319/70 ,  G01N2333/46 ,  G01N2500/10

Abstract: Provided is a novel screening system for a drug target antagonist based on cell life/death phenotype. Specifically, on the basis of a target protein and a conditional suicide protein FKBP 12 (F36V)-Caspase9, a screening system is designed for screening a target protein inhibitor or a degradation agent. The screening system is stable and efficient, the phenotype is obviously easy to observe, and the screening system can be used for high-throughput screening.

公开(公告)号：US20240191196A1

公开(公告)日：2024-06-13

申请号：US18511513

申请日：2023-11-16

Applicant: St. Jude Children's Research Hospital, Inc. ,  National University of Singapore

Inventor： Dario CAMPANA ,  Yu-Hsiang CHANG

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/00

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C12N5/0087 ,  C07K2319/00 ,  C07K2319/70 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20240182539A1

公开(公告)日：2024-06-06

申请号：US18581048

申请日：2024-02-19

Applicant: Akston Biosciences Corporation

Inventor： Thomas M. Lancaster ,  Todd C. Zion

IPC: C07K14/62 ,  C07H21/04 ,  C12N5/16

CPC classification number: C07K14/62 ,  C07H21/04 ,  C07K2319/30 ,  C07K2319/70 ,  C12N5/16

Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.